2023 World Conference on Lung Cancer (Posters)-EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer

EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the association between programmed cell death-ligand 1 (PD-L1) expression and the efficacy of alectinib in patients with ALK-rearranged lung cancer. The researchers collected data from 225 patients with ALK-rearranged lung cancer who were treated with alectinib as a first-line therapy. They evaluated the baseline PD-L1 expression levels in 56 treatment-naïve patients using immunohistochemistry. The study found that among the eligible patients, 53.6% were PD-L1 negative, 33.9% had low PD-L1 expression, and 12.5% had high PD-L1 expression. The objective response rate of the enrolled population was 85.7%, with no significant association between PD-L1 positivity and response rate or progression-free survival. However, patients with high PD-L1 expression showed a trend towards longer progression-free survival. Therefore, the study concludes that PD-L1 expression cannot predict the efficacy of alectinib in ALK-positive non-small cell lung cancer patients, and PD-L1 expression is not a universal biomarker for ALK tyrosine kinase inhibitors. The findings suggest that other factors may influence the response to alectinib in ALK-positive lung cancer patients. This study contributes to the understanding of the role of PD-L1 expression in targeted therapy for metastatic non-small cell lung cancer and provides insights into the personalized treatment strategies for this patient population.

Asset Subtitle

Xinyu Liu

Meta Tag

Speaker Xinyu Liu

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

programmed cell death-ligand 1

PD-L1 expression

alectinib

ALK-rearranged lung cancer

first-line therapy

immunohistochemistry

baseline PD-L1 expression levels

objective response rate

progression-free survival

ALK tyrosine kinase inhibitors